8,792 Results

Phase III SPARTAN study of Erleada shows reduced risk of prostate cancer.- Janssen Pharma.

 Added 15 hours ago

Janssen Pharmaceutical presented a post-hoc analysis from the Phase III SPARTAN study that showed treatment with Erleada (apalutamide) significantly reduced...

FDA issues a Complete Response Letter to Evolus for DWP 450 a proposed treatment for glabellar lines.

 Added ago

Evolus, Inc.has announced updates related to the regulatory progress of its pending Biologics License Application (β€œBLA”) for DWP 450 (prabotulinumtoxinA)...

Pfizer announces Phase III study of Lyrica for patients with pediatric epilepsy.

 Added 15 hours ago

Pfizer Inc. announced positive top-line results of a Phase III study examining the use of Lyrica (pregabalin) Oral Solution CV...

ENGAGE AF-TIMI 48 trial of Lixiana shows reduced rates of intracranial haemorrhage for patients with atrial fibrillation.- Daiichi Sankyo.

 Added 1 day ago

Daiichi Sankyo Europe announced new sub-analysis data from the ENGAGE AF-TIMI 48 trial, which demonstrates that patients with atrial fibrillation...

FDA approves Aimovig for prevention of migraine.- Novartis + Amgen.

 Added 1 day ago

Novartis has announced that the FDA has approved Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is...

ECE 2018 – 20th European Congress of Endocrinology 19 - 22 May 2018 Barcelona, Spain

 Added 2 days ago

ECE 2018 – 20th European Congress of Endocrinology 19 - 22 May 2018 Barcelona, Spain

ECE 2018 – 20th European Congress of Endocrinology is organised by the European Society of Endocrinology (ESE) and will be held from May 19 – 22 at Barcelona International Convention Centre

World IBD Day 2018

 Added 2 days ago

World IBD Day 2018

World IBD Day takes place on May 19 each year to unite people worldwide in the flight against Crohn’s disease and ulcerative colitis.

Positive follow up data from Phase III ALEX study of Alecensa shows reduced risk of disease progression or death in ALK positive NSCLC.- Genentech/Roche

 Added 2 days ago

Genentech, a member of the Roche Group announced follow-up data from the Phase III ALEX study, showing that as an...

FDA approves Lucemyra to mitigate opioid withdrawal symptoms.- US WorldMeds

 Added 2 days ago

US WorldMeds announced that the FDA approved Lucemyra (lofexidine) for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation...

Phase III study of Epidiolex in Lennox-Gastaut Syndrome published in NEJM.- GW Pharma.

 Added 2 days ago

The second of two phase III studies showing that Epidiolex (cannabinoid) from GW Pharma, cut seizures in patients with the...

Load more